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Phosphoinositide 3-kinase δ (PI3Kδ), a lipid kinase consisting of a catalytic (p110δ, encoded by 
PIK3CD) and a regulatory subunit (p85, encoded by PIK3R1), generates the second messenger 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in the plasma membrane of leukocytes down-
stream of antigen and cytokine receptors.1 Signaling via PDK1, AKT, mTOR and downstream tar-
gets such as FOXO1, contributes to the metabolic and transcriptional changes required for the ex-
pansion, differentiation and effector function of lymphocytes.1 Activating germline mutations in 
PIK3CD cause the immune dysregulatory disease activated PI3Kδ syndrome (APDS), usually pre-
senting with recurrent sinopulmonary infections in childhood, herpesvirus infections and CD4+ 
lymphopenia, underscoring the important role of balanced p110δ activity in human adaptive im-
munity.1,2 Ablation of p110δ in mice leads to aberrant T cell responses and intestinal 
inflammation.3,4 In humans, immune dysregulation including severe colitis is present in many can-
cer patients who are treated with the p110δ-specific inhibitor Idelalisib.5 Recently, one patient with 
autosomal recessive deficiency of p85α6 and two patients with loss-of function mutations in p110δ7  
have been described who developed humoral immunodeficiency and colitis.  
 
We report a child of consanguineous parentage (fig.1A) who presented at 9 years with bruising 
and upper gastrointestinal bleeding in association with profound immune-mediated thrombocyto-
penia. His thrombocytopenia was refractory to corticosteroids, high dose immunoglobulin and 
splenectomy, culminating in an intracranial bleed requiring surgical evacuation. Immunosuppres-
sion was then intensified with cyclosporine, azathioprine and a course of the B-cell-depleting agent 
Rituximab, with eventual platelet recovery. However, over the next few months he developed first a 
severe pneumonia followed by intractable diarrhea and striking (~30%) weight loss. Endoscopy 
revealed enterocolitis, which histologically showed marked apoptosis of crypt epithelial cells, eo-
sinophil and neutrophil infiltration, crypt distortion and crypt abscess formation, with increased 
CD3+ cells but a paucity of B cells and plasma cells in the lamina propria (fig.1B-C). Viral inclusion 
bodies were visible, indicating active CMV replication in the gut, accompanied by CMV viraemia 
(1.8x104 copies/mL); norovirus genogroup 2 RNA was also detected in stool.  Flow cytometric ex-
amination of peripheral blood revealed largely normal T cell numbers, modestly reduced naïve T 
cells, unexceptional T cell mitogenic responses and detectable FOXP3-positive regulatory T cells 
(supplementary table 1 and supplementary fig.1). Peripheral blood was enriched for 
effector/memory CD8+ T cells, which expressed high levels of the transcription factor TBET and 
perforin (fig.1D-E). B cell numbers were low with no class-switched memory B cells and subnormal 
immunoglobulin levels (IgG 2.5g/L and IgM 0.25g/L), consistent with prior Rituximab therapy 
and/or a primary B cell abnormality (supplementary table 1). 
 
The patient was treated with total parenteral nutrition and an empiric combination of anti-
inflammatory (mesalazine) and antiviral (ganciclovir, foscarnet) therapy, but continued with torren-
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tial diarrhoea (3L/day) until the addition of immunosuppression (corticosteroid, cyclosporine, in-
fliximab). Clinical improvement was accompanied by amelioration of inflammatory changes on re-
peat endoscopic examination. However, weaning of immunosuppressive treatment led to relapse 
of his gut disease, indicating chronic immune-mediated inflammation.  
 
Haematopoietic stem cell transplantation (HSCT) was therefore performed as a potentially curative 
procedure. After reduced intensity conditioning (fludarabine 150 mg/m2, melphalan 140mg/m2, 
alemtuzumab 0.6mg/kg), the patient received bone marrow containing 6.9x106 CD34+ cells/kg from 
an 11/12-matched CMV+ve unrelated donor. Cotrimoxazole, foscarnet, liposomal amphotericin, 
and intravenous immunoglobulin were administered as anti-infective prophylaxis with a combina-
tion of cyclosporine and mycophenolate mofetil to prevent graft versus host disease. Unfortunately 
we observed transplant rejection with early autologous lymphoid reconstitution. We therefore pro-
ceeded to a second transplant, using a more myeloablative conditioning regimen (treosulfan 
42mg/m2, fludarabine 150mg/m2, alemtuzumab 1mg/kg) and peripheral blood stem cells (CD34+ 
dose 5.3x106/kg) from an alternative partially mismatched (11/12) unrelated donor. On this occa-
sion he achieved 100% donor chimerism including lymphoid reconstitution and sustained remis-
sion of enterocolitis. Both transplants were complicated by low level CMV viraemia (<2000 cop-
ies/ml) and chronic norovirus genogroup 2 in stool. Despite the latter and prior history of prolonged 
gut failure, the patient required only 9 days’ parenteral nutrition in the wake of his first transplant 
and was otherwise managed with nasogastric feeding and later diet.  His 2nd transplant was also 
complicated by HSV (fever, viraemia, herpetic skin lesion – managed with high dose IV acyclovir) 
and an asymptomatic pericardial effusion as well as mild pancreatitis (max amylase 600 U/L) 
which resolved with conservative management. Six months after transplant, the patient returned to 
the Middle East in a stable condition without signs of enterocolitis or infection and was lost to fol-
low-up.  
 
Suspecting a monogenic immune disorder, we later carried out whole exome sequencing of patient 
genomic DNA and found the private homozygous frameshift variant c.703_723delinsGT in 
PIK3CD, confirmed by Sanger sequencing (fig.1F). The 21bp deletion coupled to a two bp 
insertion in exon 5 introduces a premature stop codon (p.Q170Vfs*41) (fig.1G). Rare (<0.001 allele 
frequency) variants of unknown significance in other immune-related genes were excluded on the 
basis of poor fit to previously reported phenotypes (TCIRG1, KDM6A, PLCG2) or autosomal re-
cessive inheritance (ACP5, STK4), respectively (supplementary table 2). 
 
In accordance with the expected role of PI3Kδ and absence of full-length protein expression (fig. 
2A), patient-derived T lymphoblasts were profoundly impaired in their ability to generate PIP3 upon 
TCR engagement (fig.2B). TCR- and IL-2-induced phosphorylation of AKT was also reduced in 
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CD4+ and CD8+ T lymphoblasts, as was IL-2-induced phosphorylation of the mTOR target S6 
(fig.2A and supplementary fig.2). Glycolysis stress test showed impaired IL-2-stimulated glycolysis 
and glycolytic reserve in patient cells, similar to the behaviour of CD4+ and CD8+ T cells treated 
with Idelalisib (fig.2C-D). These findings show that germline p110δ deficiency impairs lymphocyte 
metabolism, which we hypothesised might contribute to immunodysregulation through altered T 
cell polarization and behaviour.   
 
To investigate the cellular immunophenotype within the patient’s inflamed gut, we performed im-
munohistochemistry on colonic biopsies taken prior to HSCT. Relative to healthy age-matched 
control tissue, there was a modest expansion of CD8+ T cells in the lamina propria and a decrease 
in the CD4+ to CD8+ T cell ratio (supplementary fig.3). Additionally, we observed a substantial in-
crease in lymphocytes expressing the transcription factor TBET and perforin within both CD8+ and 
CD8- T cell compartments ( supplementary fig.4).  
Owing to the paucity of patient material we were unable to assess directly the function of specific 
leukocyte subsets but mouse models of PI3Kδ deficiency imply wide-ranging impairments of T-
regulatory function, B cell help and CD8+ T cell memory.3,4 Similar to our patient, p110δ kinase-
dead mice spontaneously develop inflammatory bowel disease with crypt abscesses.3 In these 
mice, thymic output of Tregs was normal, but Treg trafficking and suppressive activity including IL-
10 secretion were disturbed.4 p110δ kinase-dead mice make weaker responses to antigen expo-
sure than WT mice, both in vivo and in vitro3,8, despite apparently normal proliferation and metabol-
ic reprogramming of CD8+ T cells after stimulation of the TCR and the IL-2 receptor9,10. Secretion 
of IFN-γ by effector/memory CD8+ T cells was however significantly reduced by inhibitors of 
p110δ11 and AKT9, consistent with reduced production of IFN-γ in patient cells and potentially rele-
vant to viral susceptibility. This primary immunodeficiency thus highlights the central importance of 
regulated PI3Kδ activity for immune homeostasis and protective immunity in humans as in mice. 
Germline autosomal recessive deficiency of PIK3CD has recently been reported in a total of 3 
kindreds (supplementary table 3), though two siblings had a second concurrent immune disorder, 
complicating interpretation of their phenotype7,12,13.  Of the remaining four patients, all presented 
with hypogammaglobulinemia and recurrent sinopulmonary infections, some including severe and 
opportunistic pneumonias. Immune dysregulatory phenomena were also frequent, including 
inflammatory bowel disease, autoimmune hepatitis and juvenile idiopathic arthritis. Their 
management involved immunoglobulin replacement and antimicrobial therapy for acute infections, 
together with anti-inflammatory (mesalazine) or immunosuppressive (steroids and 6-
mercaptopurine) therapy where indicated for autoimmune complications.7,12,13 Although B and NK 
cell numbers were very low in some patients, others had normal counts and standard laboratory 
measures of T cell number and function were generally unremarkable. Therefore a high index of 
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suspicion for an underlying monogenic cause is required in this setting. 
In summary, we report a child with homozygous germline loss-of-function mutation in PIK3CD, who 
developed refractory immune thrombocytopenia, inflammatory bowel disease and susceptibility to 
infection, cured by HSCT. The immune defect was characterized by defective PI3Kδ signaling, al-
tered T cell metabolism and a prominent infiltrate of cytotoxic lymphocytes in the gut lamina 
propria. Our experience emphasises the potentially life-threatening nature of immune dysregulation 
in this condition, albeit we were able to gain short-term control with a cocktail of antiviral and im-
munosuppressive drugs. By analogy with related conditions such as CTLA4 deficiency and STAT3 
gain-of-function, HSCT remains an attractive option in severe immune dysregulation of monogenic 
origin. In the case of therapy with p110δ-specific small molecule inhibitors, we can conclude that 
autoimmune phenomena such as colitis arise from the same on-target activity that delivers thera-
peutic benefit by breaking tolerance to malignancy.  
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Figure Legends 
 
Figure 1: PIK3CD mutation in a patient with immunodeficiency and immune dysregulation.  
(A) Pedigree.  
(B) Haematoxylin & eosin staining showing colitis and crypt abscess formation. 
(C) Immunostaining for CD3 (gold) and CD20 (purple); P1, patient; HD, healthy donor.  
(D) CCR7 and CD45RA staining and quantification of memory CD8+ cells among CD25-CD8+ 
cells. 
(E) Expression of perforin and transcription factor TBET in naïve and memory CD8+ T cells. 
(F) Sanger sequencing confirming frameshift deletion plus 2bp insertion.  
(G) p110δ schematic showing p.Q170Vfs*41 and previously reported mutations. 
 
 
 
Figure 2: Functional impact of PIK3CD mutation.  
(A) Immunoblotting of p110δ, AKT, pAKTT308, pERKT202/Y204, pS6S235/236 and beta-actin in control 
(HD) and patient (P1) CD4+ and CD8+ T lymphoblasts with and without CD3 stimulation.  
(B) PIP3 quantification before/after TCR stimulation.   
(C) and (D) Extracellular acidification rate (Seahorse assay) and quantification of glycolysis in IL-2-
stimulated T lymphoblasts of HD and P1 (C) or HD cells treated with Idelalisib (D). Three inde-
pendent experiments with 5-8 technical replicates each; values are plotted as mean of three time 
points for each injection and each replicate (**p<0.01 and ***p<0.001, Mann-Whitney U test). 
 
 
 
 
 


  
SUPPLEMENTARY INFORMATION 
 
Methods 
Patient 
Patient and controls were recruited with written informed consent of the individuals and/or their par-
ents to participate in research, approved by the National Research Ethics Service. Patients were 
recruited via the Great North Biobank (10/H0906/22) and healthy donors were recruited via the Ox-
ford Gastrointestinal Illness biobank (16/YH/0247). 
 
Whole exome sequencing  
Whole exome capture from patient whole blood DNA was achieved using the Agilent SureSelect V5 
kit and libraries subsequently prepared for paired-end sequencing. Libraries were sequenced on an 
Illumina NextSeq instrument by a commercial sequencing provider (Oxford Gene Technology, UK). 
Read quality was assessed using the FastQC and MultiQC tools.1,2 Reads were aligned to the hg19 
assembly of the human reference genome, and analysed according to Genome Analysis Toolkit 
(GATK) best practices3, as follows: the raw alignment was realigned around indels, quality scores 
recalibrated (BQSR), and duplicates marked using the Picard suite. Genotyping was performed us-
ing a combination of the HaplotypeCaller from GATK in gVCF mode, and JointCalling program lev-
eraging an in-house exome catalogue. To avoid false positive calls, variant quality score recalibration 
(VQSR) was performed on the raw variant callsets for indels and SNPs. Downstream analysis was 
carried out using the web-based analytics application Ingenuity Variant Analysis (Qiagen) with the 
following selection criteria: call quality ≥20, read depth ≥10, allele fraction ≥45%; allele frequency 
≤0.01% (ExAc); frameshift, in-frame indel, stop codon change, deleterious missense (by SIFT/Poly-
phen), or splice site disruption. The candidate PIK3CD variant was validated by Sanger sequencing 
(SourceBioscience) in patient genomic DNA, following PCR amplification using primers designed 
with Primer3web version 4.1.0 (forward primer: GGCCTCCACGAGTTTGACT, reverse primer: 
GCGGATGACTGAGGAGTTTC). 
 
 
PBMC isolation, generation of T cell lines and T cell maintenance 
PBMCs were isolated by means of density centrifugation over Ficoll-Paque and resuspended in 
complete RPMI media. For T cell expansion, either of the following 2 methods was used: 1) Cells 
were cultured for 72 hrs in the presence of anti-CD3 (1ug/ml), anti-CD28 (1ug/ml) and IL-2 (20 
ng/ml). Once the T cells were differentiated to T cell blasts, a further expansion was done in the 
presence of IL-2 for another 72-96 hrs. 2) T cells were expanded from 0.3x106 total PBMCs by 
stimulation with phytohaemagglutinin (PHA, 1 μg/mL; Remel) in the presence of 2.5x104 irradiated 
allogeneic (45 Gy) PBMCs  and cultured for 21 days in IL-2 containing medium (500 U/mL) as pre-
viously described.4 For the generation of T cell lines, cells were FACS-sorted to >98% purity based 
  
on the surface expression of CD3+CD4+CD8– and CD3+CD8+CD4– marker combinations (antibodies 
used, and surface staining methodology as described in the section “analysis of surface marker 
expression”). T cells were expanded by culturing 5x105 cells in the presence of 2.5x104 irradiated 
(45 Gy) allogeneic PBMCs/50 µl culture for 21 days in medium supplemented with IL-2 (500 U/mL). 
Cell sorting was performed using a FACSAria III (BD Biosciences). 
T cell lines were cultured thereafter in complete RPMI with L-glutamine (Sigma) supplemented with 
5 % (v/v) human serum (NHS Blood Center Oxford), non-essential amino acids (Gibco); 1 mM so-
dium pyruvate (Gibco) and 100 U/mL penicillin and 10 µg/mL streptomycin (Sigma), hereafter called 
complete medium. Where indicated 500 U/mL IL-2 was added to the culture medium (produced in 
house from IL-2T6 culture supernatants). 
 
PIP3 quantification 
PIP3 was quantified as described5. T cells were isolated from PBMCs using immunomagnetic nega-
tive selection kit (Stemcell T cell isolation kit). The purified T cells were stimulated with anti-CD3 
(1µg/ml) and anti-CD28 (2µg/ml) antibodies followed by crosslinking with goat anti-mouse IgG 
(1:500) antibodies for 1 min at 37˚C. After stimulation of T cells, reactions were terminated by addi-
tion of 750 µl kill solution and samples were immediately frozen. Samples were kept in a freezer at 
-80°C until they were processed. Samples were thawed and 10 µl of C16/C17 PIP2 and PIP3 internal 
standard (ISD) was added. After 5 min at room temperature, 725 µl CHCl3 and 170 µl 2M HCl were 
added to the samples. After that, samples were centrifuged and the lower organic phase was col-
lected. 708 µL of pre-derivatisation wash (upper phase) was added, vortexed and samples were 
centrifuged again. The lower phase was then collected in a fresh tube for derivatisation. 50 µl 2M 
TMS-diazomethane was added to the lipid extracts and they were incubated for 10 min at room 
temperature. The reaction was stopped by addition of 6 µl of glacial acetic acid and the samples 
were washed twice with 700 µl post-derivatisation buffer (upper phase). After the final wash, 100 µl 
of MeOH:H2O (9:1) were  added to the samples and they were dried under a stream of nitrogen at 
room temperature. Samples were then re-dissolved in 80 µl of MeOH, sonicated and 20 µl of water 
was added. The samples were then sent for a mass spectrometry analysis Samples were analysed 
on a ABSciex QTRAP 4000 connected to a Waters Acquity UPLC system. Integrated area of PIP3 
was corrected for recovery against the PIP3 internal standard and then normalized to the integrated 
area of PIP2 corrected for recovery against the PIP2 internal standard. The Mass spec data are 
expressed as ratio of the quantity of the intracellular PIP3 divided by that of the PIP3 internal standard 
and normalized according to the intracellular PIP2 divided by that of the PIP2 internal standard.  
 
Analysis of T cell receptor and IL-2 receptor signaling by immunoblotting 
T cell lines were extensively washed before serum starvation for 4h in RPMI medium without sup-
plements. Cells were resuspended at 5 x106 cells/mL and aliquoted as 100µl per test tube. Cells 
were then cooled on ice for 15 min. For cell activation via the TCR, cells were incubated with 1µg/mL 
  
OKT3 (Biolegend) and 2µg/mL anti-CD28 on ice for 5 min followed by addition of 5µg/mL goat anti-
mouse crosslinking antibody (Biolegend) and a further 5 min incubation on ice. Stimulation was 
achieved by placing the cells into a 37°C water bath for 5 min. For unstimulated cells, the antibodies 
were added but the cells were not warmed to 37°C. For cell activation via the IL-2 receptor, cells 
were stimulated with 100ng/mL rhIL-2 (Peprotech) for the indicated times. Cells were then lysed in 
ice-cold lysis buffer, and lysates were separated by electrophoresis, transferred to a PVDF mem-
brane (Immobilon-P, Millipore) and probed for various signaling components by western blot, using 
the following antibodies (from Cell Signaling Technology, unless otherwise indicated): anti-p110d (H-
219) (Santa Cruz Biotechnology; clone Sc7176), anti-phospho-STAT5 (Tyr694) (D47E7) Rabbit mAb 
(# 4322), anti-phospho-AKT (Thr308) (244F9) Rabbit mAb (# 4056), anti-AKT (11E7) Rabbit mAb (# 
4685) or anti-AKT (2H10) Mouse mAB (# 2967), anti-phospho-S6 (S235/S236) (D57.2.2E) Rabbit 
mAB (# 4858), anti-phospho-ERK p44/42 MAPK (T202/Y204) Rabbit Ab (# 9101), and anti-rabbit 
IgG or anti-mouse IgG HRP-linked secondary antibodies (# 7074, #x). Anti-histone H3 (clone D1H2; 
# 4499) and anti-bActin (C4; Santa Cruz Biotechnology, clone Sc-47778) antibodies were used as 
loading control. 
 
Analysis of AKT and S6 phosphorylation by flow cytometry 
T cell lines were starved of IL-2 for 12 hours followed by extensive washing in RPMI supplemented 
with 25mM HEPES (Sigma; Cat.# H0887) and 0.5% human serum. Stimulation was performed in 
complete RPMI by addition of IL-2 (100 U/ml). Following indicated incubation times cells were fixed 
at 37°C for 15 minutes in 3.7% Formaldehyde (Sigma; Cat.# F8775). Cells were then permeabilised 
in -20°C 90% Methanol (Merck; Cat.# 106035) on ice. Staining for phosphorylated AKT and S6 was 
performed at RT for 60 minutes in PBS supplemented with 0.5% Bovine serum albumin (BSA; 
Sigma; Cat.# A9418). Following antibodies were used for analysis: anti-pAKT(S437) (Cell signalling; 
clone: M-89-61), and anti-pS6(pS235/p236) (BD Biosciences; clone: N7-548). 
 
Ex vivo analysis of surface marker expression  
The expression of surface markers was analysed by incubating cells with the relevant antibody con-
jugates for 15 min at room temperature in PBS supplemented with 0.5% (v/v) human serum. For the 
exclusion of dead cells during the analysis, cells were stained prior to fixation using Fixable Viability 
Dye eFluor® 780 (eBioscience) according to the manufacturer’s instructions. The following fluoro-
phore-conjugated antibodies were used for analysis: anti-CD3 (BD Biosciences; clone UCHT1), anti-
CD4 (Biolegend; clone RPA-T4), anti-CD8 (Biolegend; clone SK1), anti-CD14 (Biolegend; clone 
M5E2), anti-CD19 (BD Biosciences; clone SJ25C1), anti-CD25 (Biolegend; clone MA-A251), anti-
CD45RA (Biolegend; clone HI100), anti-CD56 (BD Biosciences; clone NCAM16.2), anti-CD127 (Bi-
olegend; clone A019D5); anti-CCR7 (Biolegend; clone G043H7). 
 
Analysis of transcription factor and perforin expression in PBMC 
  
For the analysis of transcription factor and perforin expression, PBMCs were stained for surface 
markers as indicated above followed by fixation and permeabilisation using the Transcription Factor 
Staining Buffer Set (eBioscience) according to the manufacturer’s instructions. For the exclusion of 
dead cells during the analysis, cells were stained prior to fixation using Fixable Viability Dye eFluor® 
780. The following fluorophore-conjugated antibodies were used: anti-TBET (Biolegend; clone 
4B10), anti-FOXP3 (eBioscience; clone: PCH101), anti-Perforin (Biolegend; clone B-D48). 
Samples were acquired on a BD Fortessa or BD LSRII and data were analysed using FlowJo soft-
ware (Tree Star). Gating was performed using isotype or unstimulated controls. 
 
Metabolic analysis 
Glycolysis stress test XFe96 (Agilent technologies) was performed as per manufacturer’s protocol. 
CD4+ and CD8+ T cell lines were starved of IL-2 for 12 hours in complete medium followed by 
extensive washing in complete medium. Cells were plated at a density of 250,000 cells per well in 
Seahorse base media containing 1% FCS, 2µM glutamine, 1µM sodium pyruvate and 50U/ml of IL-
2 (R&D Systems). The plate was then incubated in a CO2-free incubator for one hour. Extracellular 
acidification rate (ECAR) was recorded at baseline, after glucose, oligomycin and 2-Deoxy-Glucose 
injection respectively. The assay was performed in technical replicates of 8 and repeated 3 inde-
pendent times. Glycolysis, glycolytic capacity and glycolytic reserve were calculated as per manu-
facturer’s instructions. Idelalisib (CAL101) treatment was or was not carried out for 48hr on healthy 
donor CD4+ and CD8+ T cell lines before performing the Seahorse assay as described above. 
 
Immunohistochemistry 
Immunohistochemical analysis was performed on formalin-fixed and paraffin-embedded (FFPE) co-
lonic biopsies obtained by colonoscopy. 4μm sections were stained using a Discovery Ultra auto-
stainer (Ventana Medical Systems, Tucson, AZ) using HRP-activated, or alkaline phosphatase chro-
mogenic detection kits. The following primary antibodies were used: anti-CD3; Mouse clone LN10, 
Leica; anti-CD20, clone L26, Dako; anti-CD4, Rabbit SP35, Ventana; anti-CD8, clone SP57,  Ven-
tana; anti-Perforin, clone 5810, Abcam; and anti-Tbet, clone MRQ-46, Ventana. Sections were coun-
terstained with haematoxylin. Multispectral scanning of stained slides at 10x magnification was un-
dertaken using a Vectra 3.0 Automated Quantitative Pathology Imaging System (PerkinElmer, Hop-
kinton, MA). InForm Cell Analysis software (v2.0, PerkinElmer) allowed image deconvolution. Tissue 
segmentation algorithms were developed for automated delineation of intestinal epithelium and lam-
ina propria, which was then applied to all cases, and the accuracy of segmentation was optimised 
by manual correction. Individual cells in both tissue compartments were identified using a cell seg-
mentation algorithm, based upon the identification of cell nuclei. A binary approach (positive/nega-
tive) was used to score the relative expression of each; visual cues were used to distinguish positive 
staining compared to background, and thresholds were assigned. These data were exported and 
compiled in MATLAB (v2016b MathWorks, Natick, MA).  
  
 
Statistics 
Differences were analysed using Mann Whitney U test or ANOVA using GraphPad Prism v7 
(GraphPad Software).  
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Supplementary Figures: 
 
Supplementary Fig 1 
Normal frequency of FOXP3 expression in patient CD4+ T cells. 
Intracellular staining for FOXP3 in patient (P1) and control (HD) peripheral blood CD4+ T cells. HD 
(adult): n=24, HD (7-10 years): n=5, P1 (9 years): n=1 (two independent replicates). 
 
 
 
 
  
  
Supplementary Fig 2 
Defective IL-2 signaling to AKT in p110δ-deficient CD4+ and CD8+ T cell lines.  
(A) Immunoblot showing timecourse of phosphorylation response to IL-2 in CD4+ T lymphoblasts 
from patient (P1) and control (HD). (B) Timecourse analysis and histogram examples (pAKT: 15 
minutes stimulation; pS6: 30 minutes stimulation) of AKT phosphorylation and (C) S6 phosphoryla-
tion response to IL-2 in CD4+ and CD8+ T lymphoblasts from patient (P1) and control (HD) by flow 
cytometry. Non-stimulated (ctrl) cells were used as control and results presented as relative mean 
fluorescence intensity (rMFI). Results from two independent experiments and each two technical 
replicates are shown (HD: n= 2; P1: n=1). *p<0.05, **p<0.01. False discovery rate-corrected two-
way ANOVA. 
 
 
 
 
 
 
 
  
Supplementary Fig 3 
CD8 intestinal T cell expansion in a patient with p110δ-deficiency.  
Representative immunostaining and quantification of CD4+ (gold) and CD8+ (purple) cells in patient 
(P1) and control (HD) colonic biopsy tissue sections. 
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Supplementary Fig 4 
Increased intestinal TBET and perforin staining in a patient with p110δ-deficiency. 
Immunostaining for TBET (gold; left hand panels) and perforin (purple; right hand panels) in patient 
(P1) and control (HD) colonic biopsy tissue sections. Quantification of the respective cells is shown 
below.  
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Supplementary Table 1:  
Immune parameters in patient 1 with PIK3CD p.Q170Vfs*41 variant. 
 
Parameter Patient values**  Normal range 
(units)§  
T cells 3794 - 5463 1400-2300   
CD4+ T cells 1940 - 2398 900-5500   
CD8+ T cells 1680 - 2866 400-2300   
Naïve CD4+ (CD45RA+CD27+) 324   
Naïve CD8+ (CD45RA+CD27+) 162   
Double negative T (CD4-CD8-) <1 <1(%) 
FOXP3+ (% of CD4+) T cells 5.6 6.3 (%)# 
TCRab (of T cells) 91-93 (%) 
TCRVb usage polyclonal  
HLA-DR+ T cell 13 (%) 
B cells 70 600-3100   
CD27+IgD- B absent  
NK cells 282 - 471 100-1400   
IgG 2.5* 3.7-15.0 (g/L) 
IgA 0.43 - 0.68 0.3-1.2 (g/L) 
IgM 0.25 - 0.4 0.5-2.2 (g/L) 
IgE 18 0-60 (IU/mL) 
 
** Results obtained prior to commencement of immunosuppressive therapy 
§ Units = cells/µl unless otherwise stated. 
* Subsequently maintained on immunoglobulin replacement 
# Age matched healthy donors (7-10 years old) 
 
 
 
  
  
Supplementary Table 2. Rare WES findings in IUIS-designated PID genes*. 
 
Gene Variant Gen-
otype 
ExAc Impact predic-
tions 
Gene name Associated diseases 
(OMIM) 
PIK3CD frameshift hom. 0 CADD 29.0 Phosphatidyl-ino-
sitol-4,5-Bis-phos-
phate 3-Kinase 
catalytic Subunit 
Delta 
Immunodeficiency 14, 
AD (APDS) 
 
Immune dysregulation 
& immunodeficiency, 
AR [current study] 
TCIRG1 c.170C>T 
p.Ala57Val 
T/T 0.00029 CADD 13.43 
Mutation taster: 
disease causing 
 
T Cell Immune 
Regulator 1, 
ATPase H+ 
Transporting V0 
Subunit A3 
Osteopetrosis, AR 
KDM6A c.2732G>C 
p.Ser911Thr 
C 0.000069 CADD 18.43 
Mutation taster: 
disease causing 
Lysine Demethyl-
ase 6A 
Kabuki syndrome, X-
linked 
PLCG2 c.3075C>G 
p.His1025Gln 
C/G 0.000017 CADD 9.677 
Mutation taster: 
disease causing 
PolyPhen:  
benign 
Phospholipase C 
Gamma 2 
Autoinflammation, anti-
body deficiency, and 
immune dysregulation 
syndrome, AD; Familial 
cold autoinflammatory 
syndrome 3, AD 
ACP5 c.839G>A 
p.Arg280His 
C/T 0.000008 CADD 28.1 
Mutation taster: 
disease causing 
PolyPhen:  
benign 
Acid Phosphatase 
5, Tartrate Re-
sistant 
Spondyloenchondro-
dysplasia with immune 
dysregulation, AR 
STK4 c.872G>A 
p.Arg291Gln 
G/A 0.000017 CADD 23.0 
Mutation taster: 
disease causing 
PolyPhen:  
benign 
Serine/Threonine 
Kinase 4 
T-cell immunodefi-
ciency, recurrent infec-
tions, autoimmunity, 
and cardiac malfor-
mations, AR 
 
*rare: <0.001 allele frequency; IUIS gene: PID disease genes specified by the International Union of Immu-
nological Societies (IUIS) [Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. 
International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Re-
port on Inborn Errors of Immunity. J Clin Immunol. 2018;38:96-128.] 
 
Abbreviations: 
WES, Whole exome sequencing 
OMIM, Online Mendelian Inheritance in Man 
hom., homozygous 
CADD, combined annotation dependent depletion 
APDS, Activated PI3K Delta Syndrome 
AD, autosomal dominant 
AR, autosomal recessive  
 
  
 
Supplementary Table 3.  Comparison of current and previously described patients with AR PIK3CD deficiency. 
 
Patient current P2 P3 P4 P5 P6 
PIK3CD gene variant(s) hom. c.703_723de-
linsGT 
compound het 
missense & 
premature 
stop 
hom c.2161C>T 
(plus hom variant in KNSTRN) 
hom c.1653_1653delG 
Effect on 
protein 
variant p.Q170Vfs*41 p.Q721* p.V552Sfs*26 
p110d expres-
sion 
absent reduced absent ND 
Immune 
disease 
phenotype 
age of onset 9y childhood 5m <1m 2y 2m 
infections pneumonia 
CMV colitis 
recurrent RTI, 
septic arthritis, 
PCP 
recurrent RTI, 
recurrent UTI, 
oral thrush 
PCP, 
PIV pneumonia, 
oral thrush 
recurrent RTI, 
chronic rota-
virus gastroen-
teritis, 
Klebsiella 
recurrent RTI, 
metacarpal os-
teomyelitis 
immune dysreg-
ulation 
ITP 
IBD 
mild IBD, 
autoimmune 
hepatitis 
arthritis, 
psoriasis 
  IBD (Crohn’s) 
Other clinical features   dysmorphism, feeding difficulties, 
developmental delay 
  
Laboratory 
features 
CD3+ T cell 
number 
normal¶ moderately 
low 
normal normal normal 
T cell prolifera-
tion 
normal¶¶ ND moderately reduced normal ND 
B cell number reduced 
(70-228/µl) 
near absent borderline low near absent 
(17/µl) 
near absent 
(29/µl) 
NK cell number normal present borderline low normal  
NK cell function ND reduced ND reduced  
immunoglobulins low¶¶¶ low low low borderline low 
Reference current report Zhang (2013)9 Sharfe et al (2018)8 Sogkas et al (2018)7 
  
Abbreviations (Supplementary Table 3): 
 
CMV cytomegalovirus 
hom homozygous 
IBD inflammatory bowel disease 
ITP immune-mediated thrombocytopenic purpura (platelet antibody positive) 
ND not done 
PCP Pneumocystis jirovecii pneumonia 
PIV Parainfluenza virus 
RTI respiratory tract infection 
UTI urinary tract infection 
 
¶ normal CD4 and CD8 cell numbers, reduced naïve (CD27+CD45RA+) T cells, normal 
CD4+CD25hiCD127- T regulatory cells 
¶¶ normal T cell proliferation in response to PHA, CD3 +/- IL-2, PMA & ionomycin 
 
 
 
 
 
